Open AccessOral candidiasis caused by ciclesonide in a patient with COVID-19 pneumonia: A case report and literature review
Author(s) -
Nobuhide Ohashi,
Yuka Ideta,
Ayako Takeda,
Toshinori Iwai,
Mitomu Kioi,
Akira Miyazaki,
Kenji Mitsudo
Publication year - 2021
Publication title -
sage open medical case reports
Language(s) - English
Resource type - Journals
ISSN - 2050-313X
DOI - 10.1177/2050313x211048279
Subject(s) - ciclesonide , medicine , pneumonia , candida albicans , lopinavir , incidence (geometry) , covid-19 , infectious disease (medical specialty) , microbiology and biotechnology , disease , physics , optics , asthma , inhaled corticosteroids , biology
Steroid has recently been reported as a treatment for new coronavirus disease (COVID-19). The incidence of oropharyngeal candidiasis due to the inhaled steroid ciclesonide is lower than that due to other inhaled steroids. We report the first case of oral candidiasis with COVID-19 pneumonia using ciclesonide. A 75-year-old man was hospitalized for COVID-19 pneumonia. After admission, an oral combination of lopinavir/ritonavir was administered, and ciclesonide was inhaled for 7 days. On the 14th day of hospitalization, white plaque was found in his oral mucosa. Candida albicans was identified by oral bacterial tests, and amphotericin B was initiated. On the 35th hospital day, negative result for C. albicans was confirmed. Intraoral monitoring and intervention by dental care workers are considered important for the prevention of infectious complications induced by corticosteroids.